As stated by McCutcheon et al. (2020), schizophrenia is primarily associated with dysregulation in dopaminergic and glutamatergic neurotransmission, and current antipsychotic treatments mainly target dopamine D2 receptors. This evidence concerns the gene DRD2 and schizophrenia.